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Abstract
Objective In this retrospective, single-center observational study, we investigated whether discontinuing metformin for at 
least 48 h prevents metformin-induced  [18F]fluorodeoxyglucose (FDG) uptake in all segments of the colon.
Methods Patients with type 2 diabetes who were using metformin before undergoing an FDG PET/CT scan were included. 
Two groups were created: patients who discontinued metformin for less than 48 h (< 48 h group) and patients who discontin-
ued metformin for between 48 and 72 h (≥ 48 h group). A control group comprised non-diabetic patients who were not using 
metformin before undergoing an FDG PET/CT. We visually scored the uptake of FDG in four segments of the colon—the 
ascendens, transversum, descendens, and rectosigmoid—using a four-point scale (1–4) and considered scores of 3 or 4 to 
be clinically significant.
Results Colonic FDG uptake in the ≥ 48 h group (n = 23) was higher than uptake in the control group (n = 96) in the colon 
descendens [odds ratio (OR) 14.0; 95% confidence interval (CI) 4.8–40.9; p value: 0.001] and rectosigmoid (OR 11.3; 95% 
CI 4.0–31.9; p value: 0.001), and there was no difference in the colon ascendens and transversum. Colonic FDG uptake in 
the < 48 h group (n = 25) was higher than uptake in the ≥ 48 h group (n = 23) in the colon transversum (OR 4.8; 95% CI 1.3–
18.5; p value: 0.022) and rectosigmoid (p value: 0.023), and there was no difference in the colon ascendens and descendens.
Conclusions Discontinuing metformin for 48 h before undergoing an FDG PET/CT still gives a high uptake in the distal 
parts of the colon when compared with non-diabetic patients who are not using metformin. Discontinuing metformin for 
48 h seems to be useful for scanning the more proximal segments of the colon.
Keywords [18F]fluorodeoxyglucose · PET/CT · Metformin · Radiopharmaceuticals · Drug interaction
Introduction
[18F]fluorodeoxyglucose (FDG) positron emission tomogra-
phy/computed tomography (PET/CT) is used in oncology for 
diagnosis, staging, restaging, and the assessment of response 
to therapy [1]. Several studies have found an increased FDG 
uptake—predominantly in the colon—in patients who are 
using metformin, an oral antidiabetic used in patients with 
diabetes mellitus type 2 [2–4]. Although FDG PET is not 
generally performed to study primary colorectal cancer, the 
increased uptake of FDG in the colon could still obscure 
lesions and significant findings may be missed. As it is esti-
mated that the number of patients with diabetes mellitus 
will increase with an averaged annual growth of 2.7% [5], 
nuclear medicine physicians will see more patients who are 
on metformin.
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The guidelines of the European Association of Nuclear 
Medicine (EANM) [6] recommend that patients continue 
to take antidiabetics around PET scanning. An exception is 
when PET scanning is combined with an intravenous con-
trast agent, in which case, metformin should be discontinued 
at the time of the procedure and 48 h thereafter to prevent 
metformin-associated lactic acidosis. The Society of Nuclear 
Medicine and Molecular Imaging (SNMMI) does not spec-
ify guidelines for PET procedures made in patients on oral 
antidiabetics [7]. However, several studies have suggested 
that metformin should be discontinued prior to the FDG PET 
scan [2–4], and have recommended feasible and optimal 
discontinuation periods of metformin [4, 8, 9] to limit the 
amount of FDG uptake. Even so, the results in these stud-
ies are contradictory. Studies by Oh et al. and Hamidizadeh 
et al. found that discontinuing metformin for 48 h reduced 
the intestinal FDG uptake in comparison to the group that 
continued metformin [4, 8]. Oh et al. concluded that dis-
continuing metformin 48 h before an FDG PET scan is an 
effective preparation [4]. In contrast, a study performed by 
Lee et al. demonstrated that FDG uptake in the distal colon 
remained high even after metformin had been discontinued 
for over 48 h [9].
As there is currently no consensus on the time at which 
metformin should be discontinued, we aimed to determine 
whether a metformin discontinuing period of ≥ 48 h is suf-
ficient to prevent FDG uptake in all segments of the colon 
when compared with a control group of non-diabetic patients 
who are not using metformin. In other words, does discontin-
uing metformin in patients make their colonic FDG uptake 
the same as can be expected in patients who are not taking 
this drug? In addition, we assessed whether colonic FDG 
uptake differs between patients who have discontinued tak-
ing metformin < 48 h before the procedure versus those who 
have discontinued ≥ 48 h before.
Methods
Study design and patients
We conducted a retrospective, single-center observational 
study between January 2018 and September 2018 in diabetic 
patients who had been using metformin before undergoing 
an FDG PET/CT scan in Isala hospital, Zwolle, a tertiary 
referral and a 1103-bed regional hospital in The Netherlands. 
We compared these data with a control group of non-diabetic 
patients who had not been using metformin. As metformin 
is routinely discontinued in patients for 48 h, we received 
an ethical exemption in writing from the Medical Ethics 
Committee of the Isala hospital, in Zwolle in The Neth-
erlands (Reference number 190701), as this study did not 
require formal approval according to Dutch law. However, 
all patients gave their approval for the use of their data for 
this evaluation, in agreement with Dutch privacy laws.
Diabetic patients who had been using metformin before 
undergoing an FDG PET/CT scan and gave approval for 
using their data for this study were included. We excluded 
patients with a known colonic malignancy or inflammatory 
bowel diseases in the medical records, patients who received 
PET scans that did not cover the abdomen, patients who had 
discontinued metformin for > 72 h, and cases with incom-
plete data, such as an unknown metformin discontinuation 
period or unknown metformin dosage. In patients who had 
received multiple scans within this period, only the first 
scan was analyzed. At the Isala hospital, Zwolle, patients 
who are using metformin are instructed to withhold met-
formin for 48 h prior to a PET/CT scan as usual care, but 
in practice, discontinuation periods may vary. Based on the 
actual reported time of discontinuing metformin, we cre-
ated two groups: patients who had discontinued metformin 
for < 48 h (< 48 h group) and patients who had discontinued 
metformin for ≥ 48 to ≤ 72 h (≥ 48 h group). Patients in the 
control group were selected from non-diabetic patients who 
had not been using metformin and underwent an FDG PET/
CT on the same or next day as the metformin patients. For 
each patient who had been using metformin, we included 
two consecutive patients in the control group.
For each patient, we recorded the following characteris-
tics: age, sex, body mass index (BMI; kg/m2), blood glucose 
level (mmol/L), and FDG dose (MBq/kg). In the metformin 
group, we also asked patients about their daily metformin 
dose, insulin usage, and their self-reported discontinuation 
period of metformin (in hours).
Patient preparation
All patients were instructed to fast for at least 6 h and—if 
applicable—to withhold insulin prior to the FDG injection, 
according to standard protocol. Immediately before the 
FDG injection, patients’ blood glucose levels were meas-
ured in capillary blood obtained from a finger-stick with 
an Accu-Chek glucometer (Roche diagnostics). When the 
patients’ blood glucose reached a level that was higher 
than 15 mmol/L, the PET/CT scan was canceled, and the 
patients were scheduled for another appointment with addi-
tional instructions or by emphasizing their adherence to the 
instructions, depending on the cause of the high blood glu-
cose level prior to PET scanning.
PET/CT acquisition and reconstitution
PET/CT scans were acquired on a Vereos PET/CT (Philips 
Healthcare) or Ingenuity TF PET/CT (Philips Healthcare). 
The injected FDG activity (A, MBq) was based on the body 
weight of the patients (w, kg) and the acquisition time per 
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bed position (t in seconds) using the following quadratic 
equation: A = 5.2w
2
t
 (MBq). Patients were scanned 60 min 
after FDG injection. Images were acquired over 10–16-bed 
positions—taking 72/144 s each—based on a scan from the 
crown to mid-thigh or the crown to the middle of the lower 
leg. PET data were reconstructed in a 144 × 144 matrix size 
with a voxel size of 4 × 4 × 4  mm3 (representing a default 
transaxial field of view of 576 mm), using a default 3D 
ordered-subset iterative time-of-flight (TOF) reconstruc-
tion technique (Vereos PET/CT reconstitution settings: 3 
iterations, 15 subsets, and a 3 mm Gaussian post-smooth-
ing filter; Ingenuity TF PET/CT reconstitution settings: 3 
iterations, 43 subsets, and a relaxation parameter of 1.0), 
fulfilling EANM Research Ltd (EARL) accreditation speci-
fications [10]. A non-contrast CT scan that was used for 
attenuation correction was obtained using the following 
parameters: 120 kV, 40–200 mAs rotation time of 0.5 s, and 
4 mm slice thickness.
Data analysis
We randomized and anonymized the obtained PET scans 
through the use of specific settings of our picture archiv-
ing and communication (PACS) system (Sectra IDS7). This 
ensured that the researchers were blinded to the underlying 
study group conditions, such as the use of metformin. We 
visually analyzed the FDG uptake in the colon on dedicated 
workstations (Sectra IDS7). The following segments of the 
colon were investigated: the ascendens (from the cecum to 
the hepatic flexure), transversum (from the hepatic flexure 
to the splenic flexure), descendens (from the splenic flexure 
to the sigmoid colon), and rectosigmoid colon (from the sig-
moid colon to the anus, excluding the rectal sphincter). The 
rectosigmoid colon was included, because the presence of 
rectal cancer and, thus, uptake in the rectum are not unusual 
[11]. The uptake in the rectal sphincter was excluded.
Two expert nuclear medicine physicians (B. V., P. J.) and 
one trained researcher (H.K.), who were blinded to the study 
group conditions, independently conducted the visual analy-
sis. The four-point scale method of Gontier et al. [2] was 
used to score the uptake in the colon, whereby a score of 
1 = lower uptake than background hepatic activity, a score of 
2 = similar uptake to hepatic activity, 3 = moderately higher 
uptake than hepatic activity, and 4 = intense and diffuse 
uptake. A score of 3 or 4 could obscure underlying tumors 
and was, therefore, assumed to be clinically relevant. When 
the rating differed, the results were discussed among the 
three graders to reach a consensus.
Statistical analysis
We analyzed the data using SPSS Statistics version 25 
(IBM). The normal distribution of the continuous variables 
was verified using the Shapiro–Wilk test in combination with 
the normal Q–Q plots. When normally distributed, data were 
compared using the independent t test (two-tailed), or when 
not normally distributed, the Mann–Whitney U test (two-
tailed) was used. A Chi-squared test (two-sided) was per-
formed when appropriate. For the visual analysis, we deter-
mined whether there was a significant difference in gradings 
of 1–2 (low grade) and 3–4 (high grade) between the control 
group and the ≥ 48 h group and between the < 48 h group 
and ≥ 48 h group. These dichotomic data were analyzed by 
calculating the odds ratio (OR) in combination with the 95% 
confidence intervals (CI). When the number in a group was 
zero, we used Fisher’s exact test. For all analyses, p values 
of < 0.05 were considered to be statistically significant.
Results
Patient characteristics
In the total group of 126 diabetic patients, 80 patients used 
metformin and were considered for inclusion in this study, 
32 of whom were excluded, resulting in the overall inclusion 
of 48 patients on metformin. Reasons for exclusion were 
unclear metformin dosage (n = 11), patients were suffering 
from colonic malignancies or inflammatory bowel diseases 
(n = 6), unclear metformin discontinuation period (n = 5), 
incomplete data (n = 4), multiple scans of which only the first 
scan was included (n = 3), scans did not include the abdomen 
(n = 2), and technical issues with the scanner (n = 1). Of the 
48 patients using metformin, 23 reported having discontin-
ued < 48 h and 25 had discontinued ≥ 48 h. A total of 96 
patients were included in the non-diabetic control group. 
Between the three groups, there were no differences in gen-
der, BMI, and injected FDG activity. Between the < 48 h 
group and ≥ 48 h group, there were no differences in the 
daily metformin dose, age, blood glucose levels, and insulin 
use. As expected, patients in the two metformin groups were 
significantly older and had a higher blood glucose level than 
those in the control group (Table 1). 
FDG uptake in the colon
Uptake of FDG in the colon for the four segments varied 
between the three groups. Overall, high-grade uptake was 
rarely seen in the control group, but was more common in 
both metformin groups, despite the patients having discon-
tinued their metformin use. Within the metformin groups, 
discontinuing for a shorter period led to higher uptake than 
discontinuing for a longer period. A higher FDG uptake 
(grades 3–4) was most frequently seen in the < 48 h group 
[a total of 60 segments (65.2%)], followed by the ≥ 48 h 
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group [41 segments (41.0%)], and high uptake was 
least frequently seen in the control group [52 segments 
(13.5%)].
The uptake of FDG also varied between the four seg-
ments (Table 2). A high uptake (grade 3–4) in each group 
was located in the rectosigmoid (100% in the < 48  h 
group, 76.0% in the ≥ 48 h group, and 21.9% in the control 
group). Examples of different gradings in four patients are 
presented in Fig. 1, while the results of the comparison of 
the different groups are presented below.
Metformin discontinuation ≥ 48 h versus control
Our results demonstrate that even when patients discon-
tinue metformin use for 48 h, a higher FGD uptake is still 
seen more frequently than in the control group. A com-
parison between the group in which metformin had been 
discontinued for ≥ 48 h and the control group revealed 
that the colonic FDG uptake in the ≥ 48 h group was sig-
nificantly higher in the colon descendens (OR 14.0; 95% 
CI 4.8–40.9; p value: 0.001) and rectosigmoid (OR 11.3; 
95% CI 4.0–31.9; p value: 0.001) and that uptake did not 
differ in the colon ascendens (OR 0.9; 95% CI 0.3–2.9; p 
value: 0.841) and transversum (OR 2.9; 95% CI 0.7–11.0; 
p value: 0.128) (Table 2).
Metformin discontinuation ≥ 48 h versus metformin 
discontinuation < 48 h
Our results show that a higher uptake is seen more fre-
quently in the < 48 h group than in the ≥ 48 h group. A com-
parison between the group that had discontinued metformin 
for ≥ 48 h and the group that had discontinued it for < 48 h 
revealed that the FDG uptake was significantly higher in 
the < 48 h group in the colon transversum (OR 4.8; 95% CI 
1.3–18.5; p value: 0.022) and rectosigmoid (p value: 0.023), 
and there was no difference between both metformin groups 
in both the colon ascendens (OR 2.8; 95% CI 0.7–11.0; p 
value: 0.141) and descendens (OR 2.8; 95% CI 0.8–10.0; p 
value: 0.108) (Table 2).
Discussion
Our results demonstrate that even when discontinuing met-
formin for 48 h before FDG PET scanning, colonic FGD 
uptake remains high when compared to patients who have 
not taken metformin at all. In other words, discontinua-
tion periods of 48–72 h still do not normalize colonic FDG 
uptake to the level observed in patients who have not been 
using metformin. This increased uptake was observed 
to be especially high in the distal segments of the colon 
Table 1  Characteristics of the study population
N/A not applicable, BMI body mass index, FDG  [18F]fluorodeoxyglucose
*Statistically significant
Characteristics  < 48 h group  ≥ 48 h group Control group p value
 < 48 h group 
vs. control 
group
 ≥ 48 h group 
vs. control 
group
 < 48 h group 
vs. ≥ 48 h 
group
Number of patients 23 25 96 N/A N/A N/A
Age (years), median (25th–
75th perc.)
70.0 (63.0–75.0) 69.0 (63.0–77.5) 63.0 (57.0–70.0) 0.001* 0.015* 0.796







BMI (kg/m2), median (25th–
75th perc.)
27.7 (24.7–31.8) 26.6 (25.3–30.8) 26.2 (24.0–29.0) 0.214 0.212 0.919
Injected FDG activity (MBq/
kg), median (25th–75th 
perc.)
3.6 (3.2–4.8) 4.1 (3.3–5.1) 4.0 (3.3–5.0) 0.595 0.992 0.683
Blood glucose level 
(mmol/L), median (25th–
75th perc.)
9.0 (7.4–11.3) 8.5 (6.5–9.5) 5.3 (5.1–6.0) 0.001* 0.001* 0.238






N/A N/A N/A 0.535
Daily dose metformin (mg), 
median (25th–75th perc.)
1000 (500–2000) 1500 (1000–2000) N/A N/A N/A 0.452
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(descendens and rectosigmoid). In the proximal segments, a 
discontinuation period of 48 h normalized colonic uptake to 
a level that did not differ to the one observed in non-diabetic 
patients who had not been using metformin.
Comparing the two metformin groups, we found that 
patients who had discontinued metformin for at least 48 h 
showed high uptake less frequently than patients who had 
discontinued metformin for less than 48 h. However, our 
results are not conclusive for all segments of the colon; FDG 
uptake in the colon ascendens and descendens did not differ 
between the two groups, whereas uptake in the transversum 
and rectosigmoid segments remained higher after the shorter 
period of metformin discontinuation.
Our results are in line with the results of a study by Lee 
et al. [9]. Although the total number of patients in the study 
of Lee et al. was larger (n = 240), the number of patients in 
the 48–72 h discontinuation group of that study was rela-
tively small (n = 12). In our study, performed in a European 
population, we included more patients discontinuing met-
formin for at least 48 h (n = 25), this contributes evidence to 
the theory that a metformin discontinuation period of 48 h 
is insufficient to prevent FDG uptake in all of the colonic 
segments. Our results contradict the results found in a study 
by Hamidizadeh et al. which showed that a discontinuation 
period of 48 h lowered the FDG uptake in all of the colonic 
segments [8]. In our study, we used a different control group 
in comparison with the studies of Lee et al. and Hamidi-
zadeh et al. [8, 9]. The study of Lee et al. compared their 
results with a diabetic non-metformin control group and the 
study of Hamidizadeh et al. used a control group of patients 
who continued metformin. The strength of our study is that 
we compared our results with a non-diabetic control group 
that had not been using metformin. This approach enabled 
us to investigate whether the FDG uptake was comparable to 
that in a group of patients where we would not expect FDG 
uptake due to the metformin. Furthermore, in our study, we 
examined the everyday practice of nuclear medicine and 
were able to demonstrate the impact of the current policy 
to discontinue metformin use 48 h prior to scanning on the 
actual FDG uptake.
Due to the low number of patients with a high-grade 
uptake per variable, we were unable to perform logistic mod-
eling and calculate an adjusted OR [12]. A larger sample 
might reveal more about potential confounders. Considering 
the characteristics of our study population, the patients who 
were using metformin were older and generally had a higher 
blood glucose level in comparison with the patients of the 
control group. However, we do not expect that these char-
acteristics influenced our results. The previous research has 
demonstrated that age does not influence the FDG uptake 
in the intestines [13]. Although a high blood glucose level 
can lead to increased muscle uptake and competition with 
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previous research—that fasting hyperglycemia did not influ-
ence the clinical value of the interpretation of the scan [6]. 
Moreover, the above-described mechanisms do not explain 
an increased colonic FDG uptake in metformin patients.
Although patients were asked to withhold insulin prior 
to the PET/CT scan, in our study, no exact data were avail-
able on when those patients discontinued their insulin use. 
Although hyperinsulinemia may increase uptake in muscles, 
there seems to be no known association of colonic FDG 
uptake with insulin [3, 13, 15].
As we were interested in whether discontinuation of met-
formin would make the colonic FDG uptake as we would 
expect in patients who had not been taking this drug and 
similar to the uptake in non-diabetic patients, we did not 
include a group of patients who had continued the use of 
metformin, as it is already known that metformin increases 
FDG uptake. Including such an additional group might have 
revealed more about the degree of lowering the FDG uptake 
in patients who had discontinued metformin compared with 
those who had continued its use.
The mechanism behind the relationship between met-
formin and FDG uptake in the colon remains unclear. Pro-
posed theories include increased lactate production—and 
higher glucose usage—in the intestine due to treatment 
with metformin [16], relocation and increase of apical 
glucose transporters (GLUT2) [16–19], processes related 
to adenosine monophosphate-activated protein kinase 
(AMPK) activation [20, 21], and the role of the increased 
intestinal microbiome [22]. A mechanism that involves a 
long-term effect as a result of exposure to metformin—
such as the upregulation of glucose transporters—might 
explain why FDG uptake remains high for some segments 
of the colon after the discontinuation of metformin. Addi-
tional research may clarify the exact mechanism behind 
the relationship between metformin and FDG uptake in 
the colon.
The results of our study raise the question of whether 
patients should discontinue metformin for even longer than 
48 h before FDG PET procedures. However, longer discon-
tinuation periods may not be feasible for patients and could 
influence their diabetic control and health, as well as gener-
ating logistic problems in patients who require urgent PET 
scans. As we see a benefit of discontinuing metformin use 
for 48 h in the more proximal segments of the colon, we still 
recommend discontinuing metformin 48 h before an FDG 
PET/CT scan. As FDG uptake—especially in the more dis-
tal segments of the colon—cannot be completely prevented, 
lesions might still be obscured and significant findings may 
still be missed.
Conclusion
Discontinuing metformin for 48 h in FDG PET/CT results 
in a high uptake in some parts of the colon when compared 
with non-diabetic patients who have not been using met-
formin. Discontinuing metformin for 48 h seems to be use-
ful for the more proximal segments of the colon, but FDG 
uptake remains high in the more distal segments of the 
colon. Discontinuing metformin for 48 h is preferable to dis-
continuing for shorter periods. The exact mechanism respon-
sible for the increased FDG uptake in the colon remains 
unknown.
Fig. 1  PET/CT images of four patients with different grades of FDG uptake in the colon, from left to right, corresponding to the four-point scale 
method of Gontier et al. [2]
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